戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ol, kanamycin, moxifloxacin, ethionamide, or clofazimine.
2  Most participants (97%) received concurrent clofazimine.
3  transferase) led to temporary withdrawal of clofazimine.
4 , 33.3% moxifloxacin, 1.5% linezolid, and 2% clofazimine.
5 ity remained above 90% for all drugs, except clofazimine.
6 ent discontinuation of either bedaquiline or clofazimine.
7 esistant mutants are also cross-resistant to clofazimine.
8 ients with pre-XDR-TB treated with BPaL plus clofazimine.
9 stance and susceptibility to bedaquiline and clofazimine.
10 followed by 2 mo of rifampin, isoniazid, and clofazimine.
11     One-half of the mice also received daily clofazimine.
12 4 mug/ml), linezolid (0.25 to 2 mug/ml), and clofazimine (0.03 to 0.25 mug/ml).
13 h/L and 111.79 mg x h/L) in adults receiving clofazimine (100 mg) daily for MDR/RR-TB and leprosy, re
14    All CSF measurements of bedaquiline (12), clofazimine (24), and delamanid (19) were below the limi
15 id, with a subset receiving cycloserine (5), clofazimine (5), delamanid (4), and bedaquiline (2).
16 majority also received linezolid (89.6%) and clofazimine (84.5%).
17 d in mice and not differently susceptible to clofazimine, a drug in clinical use proposed to engage N
18                   These results suggest that clofazimine accumulates in macrophages by forming a memb
19 observed for clarithromycin, bedaquiline, or clofazimine across treatment phases, indicating that seq
20 flux pumps and to potentiate bedaquiline and clofazimine activity in M. tuberculosis.
21              Furthermore, mice that received clofazimine after BCG vaccination exhibited significantl
22 g system specifically designed for detecting clofazimine aggregates.
23                                              Clofazimine, an FDA-approved antibiotic, accumulates and
24                            Here we show that clofazimine-an anti-leprosy drug with a favourable safet
25  formation, we synthesized a closely related clofazimine analog that does not precipitate under physi
26                                              Clofazimine and beta-lactams may have unrealized potenti
27 oresistance to bedaquiline and linezolid and clofazimine and linezolid were 0.1% and 0.3%, respective
28 general, molecular design strategy for using clofazimine and other small molecule building blocks for
29                              Combinations of clofazimine and remdesivir exhibited antiviral synergy i
30 nd other antimicrobial substrates, including clofazimine and the DprE1 inhibitors PBTZ-169 and OPC-16
31  therapy with three antibiotics: rifampicin, clofazimine, and dapsone.
32 on drugs (bedaquiline, delamanid, linezolid, clofazimine, and fluoroquinolones).
33  were classified for bedaquiline, delamanid, clofazimine, and linezolid as prevalence of phenotypic r
34 itive and resistant isolates for pretomanid, clofazimine, and linezolid was achieved at concentration
35  DST for bedaquiline, pretomanid, linezolid, clofazimine, and rifampicin using clinical M. tuberculos
36 stration (FDA)-approved drugs and identified clofazimine as a potential third agent to optimize anti-
37  strategy to identify the antimicrobial drug clofazimine as an agent that both potentiates ICB effica
38  = .022); levofloxacin AUC0-24/MIC of 118.3, clofazimine AUC0-24/MIC of 50.5, and pyrazinamide AUC0-2
39                    Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resist
40 fied a potent 4-drug oral regimen comprising clofazimine, bedaquiline, pyrazinamide, and delamanid (p
41 drug's red color, it is widely believed that clofazimine bioaccumulation results in skin pigmentation
42 the BPaLM regimen, continuing with BPaL plus clofazimine (BPaLC) provided more QALYs at lower cost th
43 (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z).
44 ug, pyrazinamide (Z), and a repurposed drug, clofazimine (C), may assist treatment shortening of drug
45                      These results show that clofazimine can be repurposed to treat cholera and open
46       Weakly basic small molecule drugs like clofazimine can be used as building blocks for endowing
47 hly using charcoal-containing agar to reduce clofazimine carryover.
48 ficacy, pharmacokinetics (PK), and safety of clofazimine (CFZ) in patients living with human immunode
49                         Here, biocrystals of clofazimine (CFZ) that form in vivo within macrophages w
50                   The mechanism of action of clofazimine (CFZ), an antimycobacterial drug with a long
51 fx) and reinforced with cycloserine (Cs) and clofazimine (Cfz), delamanid (Dlm) and pyrazinamide (Z),
52 s, alone or with additional encapsulation of clofazimine (CFZ), enhance killing of mycobacteria in vi
53  [INH], linezolid [LZD], moxifloxacin [MFX], clofazimine [CFZ], pyrazinamide [PZA], and kanamycin [KA
54                       The lowest P value for clofazimine clearance was with VKORC1 rs9923231 (P = .13
55 l responses to the pharmacological molecule, clofazimine (CLF).
56 02 milliseconds for every 1-ug/L increase in clofazimine concentration.
57 ed after 3 and 5 mo in mice treated with the clofazimine-containing and standard regimens, respective
58 ained after 3 and 6 mo of treatment with the clofazimine-containing and standard regimens, respective
59  4 mo of rifampin and isoniazid, with a 4-mo clofazimine-containing regimen: 2 mo of daily rifampin,
60  Although observational studies suggest that clofazimine-containing regimens are highly active agains
61                                          The clofazimine contribution was substantial in these experi
62 zolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, a
63                             Also unlike pure clofazimine crystals, CLDIs fragmented when heated, and
64                                  Unlike pure clofazimine crystals, isolated CLDIs placed in distilled
65 orm in subcellular spaces correspond to pure clofazimine crystals, macrophages of clofazimine-fed mic
66 t common companion drugs included linezolid, clofazimine, cycloserine and a fluoroquinolone.
67 t common companion drugs included linezolid, clofazimine, cycloserine, and a fluoroquinolone.
68  with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and pyrazinamide
69                                              Clofazimine deserves further study for the treatment of
70  developed data analysis tool, we found that clofazimine does penetrate to some extent into necrotic
71                                          The clofazimine doses used achieved substantially higher exp
72 s in children than adults receiving standard clofazimine doses.
73                                   Therefore, clofazimine enhances Tcm cell expansion, which in turn p
74 dications (amiodarone, chloroquine, suramin, clofazimine, etc.) may produce a drug-induced lipidosis
75 ts with baseline fluoroquinolone resistance, clofazimine exposure, and four or less effective drugs w
76                    The association of higher clofazimine exposures and QT interval prolongation may p
77                    Upon prolonged treatment, clofazimine extensively bioaccumulates and precipitates
78 to pure clofazimine crystals, macrophages of clofazimine-fed mice were elicited with an intraperitone
79 daily rifampin, isoniazid, pyrazinamide, and clofazimine followed by 2 mo of rifampin, isoniazid, and
80 ugs - Bedaquiline, Delamanid, Linezolid, and Clofazimine for 24-36 weeks in adults with pulmonary MDR
81  relapse rate was 7% among mice treated with clofazimine for 8 to 9 months.
82           We report 22 patients treated with clofazimine for chronic graft-versus-host disease (cGVHD
83 -resistant tuberculosis, the contribution of clofazimine for the treatment of this disease has never
84 se +/-SD, 1.0+/-0.5 log 10 cfu/mL of blood), clofazimine had the greatest bacteriostatic efficacy in
85 f the 16 compounds tested to date (including clofazimine, haloperidol and others) had measurable anti
86     A key drug for the treatment of leprosy, clofazimine has recently been associated with highly eff
87                                              Clofazimine, imaged here for the first time in necrotic
88 rance of bedaquiline, its M2 metabolite, and clofazimine in a cohort of patients treated for drug-res
89 rophylactic or therapeutic administration of clofazimine in a hamster model of SARS-CoV-2 pathogenesi
90 drug regimen with or without the addition of clofazimine in a mouse model of multidrug-resistant tube
91 described the pharmacokinetics and safety of clofazimine in children treated for multidrug/rifampicin
92    Consistent with the low concentrations of clofazimine in the skin, these results suggest that clof
93                              To test whether clofazimine-induced skin pigmentation is due to CLDI for
94 mine in the skin, these results suggest that clofazimine-induced skin pigmentation is not due to clof
95                       The mechanism by which clofazimine induces a response is unknown, but might be
96                                              Clofazimine is a poorly-soluble but orally-bioavailable
97                                        Thus, clofazimine is a promising anti-TB drug with the potenti
98                                              Clofazimine is a weakly basic, Food and Drug Administrat
99    Our results show that in an animal model, clofazimine is as effective as ampicillin in the treatme
100                                        Thus, clofazimine is safe and has encouraging efficacy in cGVH
101  analyses show that the structural target of clofazimine is the catalytically active ubiquinone-bindi
102 s the utility of bedaquiline, delamanid, and clofazimine is uncertain given their low CSF penetration
103 use of Bdq and Dlm, along with linezolid and clofazimine, is safe and effective for MDR/RR-TB patient
104 5 confers resistance towards bedaquiline and clofazimine, key drugs to combat multidrug resistant tub
105                                              Clofazimine (Lamprene) is an antimycobacterial drug that
106  and phenothiazines and have identified that clofazimine (Lamprene) shows strong antibiotic effects a
107 ifloxacin, amikacin, kanamycin, ethionamide, clofazimine, linezolid, delamanid, and bedaquiline).
108 .0), kanamycin (<=8.0), capreomycin (<=4.0), clofazimine (&lt;=0.25) and linezolid (<=2.0).
109           Consequently, we hypothesized that clofazimine may also shorten the duration of treatment f
110                                              Clofazimine may contribute to new short-course DR-tuberc
111               Our data provide evidence that clofazimine may have a role in the control of the curren
112 d bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB reg
113                We determined bedaquiline and clofazimine minimum inhibitory concentrations and did Il
114                    Upon oral administration, clofazimine molecules self-assemble into stable, membran
115  of the ETC inhibitors bedaquiline, Q203 and clofazimine on the Mtb ETC, and the value of the ETC as
116  bedaquiline) and repurposed (eg, linezolid, clofazimine, or meropenem) drugs and guided by genotypic
117 reated with the same antibiotic (ethambutol, clofazimine, or rifampin) that had been administered to
118                                  Remarkably, clofazimine outperforms ICB dose reduction or steroid tr
119 al effect of steroids on antitumor efficacy, clofazimine potentiates curative responses in anti-PD-1+
120                                Collectively, clofazimine potentiates the antitumor efficacy of anti-P
121 mine-induced skin pigmentation is not due to clofazimine precipitation and CLDI formation, but rather
122                             Mechanistically, clofazimine promotes E2F1 activation in CD8(+) T cells t
123 omas could be observed for the anti-TB drugs clofazimine, pyrazinamide, and rifampicin at a pixel siz
124 line, pyrazinamide, levofloxacin, linezolid, clofazimine) regimens, respectively.
125 r 5 months, whereas all mice treated without clofazimine remained heavily culture-positive for the en
126 thylene microbeads or treatment with soluble clofazimine rendered macrophages stiffer.
127                        Here, we describe how clofazimine represents a first-in-class mechanopharmaceu
128 s so far identified as being associated with clofazimine resistance and also seen in clinically resis
129                  To decipher bedaquiline and clofazimine resistance determinants, we combined experim
130 trations to select bedaquiline-resistant and clofazimine-resistant mutants.
131 .61 and 4.68 in mice treated with or without clofazimine, respectively (P < 0.001).
132 of participants, this included linezolid and clofazimine, respectively.
133 %-CI: 1.1-3.1; P = .02), and be resistant to clofazimine (RR: 2.3; 95%-CI: 1.5-3.6; P = .001).
134 lerae metabolism allowed us to identify that clofazimine's main target in this pathogen is the respir
135           Increased ETC activity potentiates clofazimine's production of reactive oxygen species, cau
136 el preferentially expressed by Tem cells, by Clofazimine selectively expands Tcm cells during BCG vac
137                                 In addition, clofazimine shows strong antivirulence properties, almos
138                    The resulting increase in clofazimine solubility activates this broad-spectrum ant
139 ensitivity gains are highest for ethambutol, clofazimine, streptomycin, and ethionamide as regression
140 edictions for anti-TB-agents (rifampicin and clofazimine) strikingly match recent spatially-resolved
141 olony counts were significantly lower in the clofazimine-treated mice than in the mice receiving the
142                                           In clofazimine-treated mice, skin cryosections revealed no
143                                              Clofazimine use increased Emax by 3.3-fold.
144 pic cross-resistance between bedaquiline and clofazimine was 0.4% in MDR-TB and 1% in pre-extensively
145                                              Clofazimine was added per culture and sensitivity.
146                                              Clofazimine was administered by weight-based dosing.
147                        No additive effect of clofazimine was observed after the first week of treatme
148                                       Median clofazimine wAUC was 162.94 (IQR, 130.06-263.95), >25% h
149                                              Clofazimine weekly area under the concentration time-cur
150                            Mice treated with clofazimine were culture-negative after 5 months, wherea
151 st P values for clearance of bedaquiline and clofazimine were with RFX4 rs76345012 (P = 6.4 x 10-7) a
152 fashion with either ethambutol, rifampin, or clofazimine, were tested by three conventional methods u
153 ertain drugs-fluoroquinolones, pyrazinamide, clofazimine-were predictive and should be optimized to i
154 t 2- to 8-fold increases in MICs for BDQ and clofazimine, whereas one atpE mutant exhibited a 50-fold
155                   Conversely, the antibiotic clofazimine, which increases ROS via an NADH-dependent r
156                                              Clofazimine, which is orally bioavailable and comparativ
157 onotherapy: clarithromycin, bedaquiline, and clofazimine, with only one drug administered at a time f
158  MAC bacteremia received clarithromycin plus clofazimine, with or without ethambutol, in a prospectiv

 
Page Top